Filter Results:
(925)
Show Results For
- All HBS Web
(925)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (667)
Show Results For
- All HBS Web
(925)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (667)
- January 1994
- Case
Evolving Finance Function: Judy C. Lewent at Merck & Co., Inc.
By: Timothy A. Luehrman
This case examines the career path of Merck's CFO, Judy C. Lewent, as a way of tracing changes over time in Merck's finance function. It describes the adoption of innovative quantitative analytical models, changes in job definitions and in the organization of the... View Details
Keywords: Finance; Mathematical Methods; Personal Development and Career; Organizational Design; Innovation and Invention; Pharmaceutical Industry
Luehrman, Timothy A. "Evolving Finance Function: Judy C. Lewent at Merck & Co., Inc." Harvard Business School Case 294-014, January 1994.
- January 2025 (Revised March 2025)
- Case
Gavi and the 'Next' Pandemic
By: Tarun Khanna and Kerry Herman
In 2025, CEO Dr. Sania Nishtar and her team consider the lessons the Global Alliance for Vaccine and Immunizations (GAVI) learned from the pandemic. GAVI successfully brought COVID-19 vaccines to large swaths of the undeveloped and under-developed world by pooling... View Details
Keywords: Developing Countries and Economies; Health Care and Treatment; Health Pandemics; Crisis Management; Success; Innovation and Invention; Service Delivery; Organizational Change and Adaptation; Strategic Planning; Pharmaceutical Industry; Africa
Khanna, Tarun, and Kerry Herman. "Gavi and the 'Next' Pandemic." Harvard Business School Case 725-351, January 2025. (Revised March 2025.)
- September 2024
- Article
Comprehensive Measurement of Biopharmaceutical R&D Investment
By: Amitabh Chandra, John Drum, Michael Daly, Henry Mirsberger, Samuel Spare, Ulrich Neumann, Silas Martin and Noam Kirson
Chandra, Amitabh, John Drum, Michael Daly, Henry Mirsberger, Samuel Spare, Ulrich Neumann, Silas Martin, and Noam Kirson. "Comprehensive Measurement of Biopharmaceutical R&D Investment." Nature Reviews: Drug Discovery 23, no. 9 (September 2024): 652–653.
- August 2022
- Article
Availability of New Medicines in the U.S. and Germany From 2004 to 2018
By: Katharina Blankart, Huseyin Naci and Amitabh Chandra
Importance: Germany's unique approach to coverage determination and pricing has ensured that effective medicines remain on the market, often at prices reduced through negotiation. However, less is known about trade-offs of this approach with regard to initial... View Details
Keywords: Market Entry and Exit; Price; Market Timing; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States; Germany
Blankart, Katharina, Huseyin Naci, and Amitabh Chandra. "Availability of New Medicines in the U.S. and Germany From 2004 to 2018." e2229231. JAMA Network Open 5, no. 8 (August 2022).
- October 2020
- Teaching Plan
Merck: COVID-19 Vaccines
By: Willy C. Shih
COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,... View Details
- January 2017
- Supplement
Medtronic: Making the Big Leap Forward (B)
By: William W. George and Monica Baraldi
On December 1, 2014, Medtronic announced that it had completed a $17 billion bond sale to finance the Covidien acquisition, officially completed on January 26, 2015. Medtronic’s legal headquarters moved to Ireland, while its operational headquarters remained in... View Details
Keywords: Acquisition; Medtronic; Covidien; Mission; Tax Inversion; Business Strategy; Leadership; Mergers and Acquisitions; Integration; Pharmaceutical Industry; Republic of Ireland; Europe; Minnesota; United States
George, William W., and Monica Baraldi. "Medtronic: Making the Big Leap Forward (B)." Harvard Business School Supplement 317-074, January 2017.
- December 2014 (Revised October 2017)
- Case
Social Business at Novartis: Arogya Parivar
By: Michael E. Porter, Mark R. Kramer and David Lane
Late in 2013, Novartis CEO Joseph Jimenez was considering whether or how to deepen the company's investment in Arogya Parivar, its profitable program that sold Novartis medicines in rural India while expanding access to medicine and health information to millions of... View Details
Keywords: Shared Value; India; Kenya; Vietnam; Novartis; Arogya Parivar; Social Business; Multinational Firms and Management; Competitive Advantage; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Viet Nam; Kenya; India
Porter, Michael E., Mark R. Kramer, and David Lane. "Social Business at Novartis: Arogya Parivar." Harvard Business School Case 715-411, December 2014. (Revised October 2017.)
- March 2014
- Editorial
Limits on Use of Health Economic Assessments for Rare Diseases
By: Hanna I. Hyry, Ariel Dora Stern, Jonathan CP Roos and Timothy M. Cox
Funding of expensive treatments for rare ('orphan') diseases is contentious. These agents fare poorly on 'efficiency' or health economic measures, such as the QALY, because of high cost and frequently poor gains in quality of life and survival. We show that... View Details
Hyry, Hanna I., Ariel Dora Stern, Jonathan CP Roos, and Timothy M. Cox. "Limits on Use of Health Economic Assessments for Rare Diseases." hcu016. QJM: An International Journal of Medicine 107, no. 3 (March 2014): 241–245.
- April 2014 (Revised July 2015)
- Case
Sanofi Pasteur: The Dengue Vaccine Dilemma
By: V. Kasturi Rangan, David E. Bloom, Vincent Dessain and Emilie Billaud
In 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a... View Details
Keywords: Health Testing and Trials; Product Launch; Market Entry and Exit; Emerging Markets; Pharmaceutical Industry; France
Rangan, V. Kasturi, David E. Bloom, Vincent Dessain, and Emilie Billaud. "Sanofi Pasteur: The Dengue Vaccine Dilemma." Harvard Business School Case 514-074, April 2014. (Revised July 2015.)
- October 1994
- Case
Nippon Kayaku
By: Robin Cooper, Takeo Yoshikawa and Robert S. Kaplan
Cooper, Robin, Takeo Yoshikawa, and Robert S. Kaplan. "Nippon Kayaku." Harvard Business School Case 195-068, October 1994.
- 2013
- Working Paper
Visualizing and Measuring Enterprise Architecture: An Exploratory BioPharma Case
By: Robert Lagerstrom, Carliss Baldwin, Alan MacCormack and David Dreyfus
We test a method that was designed and used previously to reveal the hidden internal architectural structure of software systems. The focus of this paper is to test if it can also uncover new facts about the components and their relationships in an enterprise... View Details
Lagerstrom, Robert, Carliss Baldwin, Alan MacCormack, and David Dreyfus. "Visualizing and Measuring Enterprise Architecture: An Exploratory BioPharma Case." Harvard Business School Working Paper, No. 13-105, June 2013.
- September 2012 (Revised November 2014)
- Case
Cialis Lifecycle Management: Lilly's BPH Dilemma
By: Elie Ofek and Natalie Kindred
How should Eli Lilly further develop and market a new indication of its highly successful erectile-dysfunction (ED) drug, Cialis, without confusing Cialis's hard-won brand equity with physicians and patients? With the final stages of clinical trials for the new... View Details
Keywords: Product Positioning; Attitudes; Brands and Branding; Pharmaceutical Industry; United States
Ofek, Elie, and Natalie Kindred. "Cialis Lifecycle Management: Lilly's BPH Dilemma." Harvard Business School Case 513-005, September 2012. (Revised November 2014.)
- May 2011 (Revised July 2012)
- Exercise
Remicade/Simponi: Confidential Instructions for Merck
By: Guhan Subramanian and Rhea Ghosh
This two-party negotiation exercise features a real-life dispute between Merck and Johnson & Johnson regarding European distribution rights to two highly lucrative drugs. View Details
Keywords: Price; Rights; Agreements and Arrangements; Negotiation Deal; Problems and Challenges; Risk and Uncertainty; Pharmaceutical Industry
Subramanian, Guhan, and Rhea Ghosh. "Remicade/Simponi: Confidential Instructions for Merck." Harvard Business School Exercise 911-044, May 2011. (Revised July 2012.)
- December 2010
- Teaching Note
Organization and Strategy at Millennium (TN) (A) & (B)
By: Julie M. Wulf
Teaching Note for 710-415 and 710-418. View Details
- April 2009
- Teaching Note
Amylin Pharmaceuticals: Diabetes and Beyond (TN)
By: Richard G. Hamermesh and Rachel Gordon
Teaching Note for [809011]. View Details
- April 2009
- Supplement
Merck: Managing Vioxx (G)
By: Robert L. Simons and Natalie Kindred
Keywords: Decision Choices and Conditions; Leadership; Customer Focus and Relationships; Pharmaceutical Industry
Simons, Robert L., and Natalie Kindred. "Merck: Managing Vioxx (G)." Harvard Business School Supplement 109-086, April 2009.
- April 2009 (Revised April 2010)
- Supplement
Merck: Managing Vioxx (F)
By: Robert L. Simons and Natalie Kindred
Simons, Robert L., and Natalie Kindred. "Merck: Managing Vioxx (F)." Harvard Business School Supplement 109-085, April 2009. (Revised April 2010.)
- April 2009
- Supplement
Merck: Managing Vioxx (D)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
Keywords: Pharmaceutical Industry
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (D)." Harvard Business School Supplement 109-083, April 2009.
- April 2009
- Supplement
Merck: Managing Vioxx (C)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
Keywords: Pharmaceutical Industry
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (C)." Harvard Business School Supplement 109-082, April 2009.
- April 2009 (Revised April 2010)
- Supplement
Merck: Managing Vioxx (B)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (B)." Harvard Business School Supplement 109-081, April 2009. (Revised April 2010.)